权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Carrier cell mediated ovarian cancer specific gene therapy

载体细胞介导的卵巢癌特异性基因治疗

基本信息

批准号：
15591754
负责人：
HAMADA Katsuyuki
金额：
$ 2.24万
依托单位：
Ehime University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2003
资助国家：
日本
起止时间：
2003 至 2004
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-15591754/
关键词：
Ovarian cancer Oncolytic adenovirus IAI.3B Promoter Carrier cell Anti-adenovirus antibody 293 cell A549 cell 坑アデノウイルス抗体

项目摘要

We constructed an oncolytic adenovirus, AdE3-IAI.3B that was introduced ovarian cancer specific IAI.3B promoter, and showed the effect of the growth inhibition in the ovarian cancer cell proliferation in vitro and in vivo (Cancer Research, 2003). The treatment by AdE3-IAI.3B is assumed the problem that all tumors relapses in 2-3 weeks further even if tumor reduction is temporarily done on about 30 days after the treatment. This is confirmed not only in the animal experiment but also in the clinical trial by using other oncolytic vectors. It is guessed that it is a cause that vector rapidly shifts to the whole body from the tumor, because the stagnation rate of vector in the tumor is few, and the stagnation time in the tumor is short. After AdE3-IAI.3B had been infected to 293 and A549 cells that had been known as an adenoviral production cell so far as a carrier cell and these carrier cells were adminstered to the nude mouse subcutaneous tumor model of ovarian cancer PA-1 and RMG-1 cel … More l that the IAI.3B promoter is high, both tumors completely disappeared and did not relapsed. On the other hand, the HEY cell tumor, whose adenoviral receptor is fewer than these cells, disappeared and the relapse was not admitted when both were used together, though the tumor did not disappear after the single cell treatment by 293 or A549 cells infected with AdE3-IAI.3B. It is well known that the second challenge of adenoviral vectors is completely blocked by the anti-adenoviral antibody production. However, the second challenge of adenovirus succeeded by using AdE3-IAI.3B infected 293 or A549 carrier cell. This restoration of the second adenoviral infection was completely blocked by 0. 4 um millicell membrane chamber and 50% blocked by 12 um millicell memebrane chamber. This was due to the infection achievement by direct carrier cell to target cell contact and carrier cell fragment to target cell contact. This infection style of oncoloytic adenovirus infected carrier cell was confirmed by the electron microscope. Less

我们构建了溶瘤腺病毒AdE3-IAI。在体外和体内实验中均显示了其对卵巢癌细胞增殖的生长抑制作用（cancer Research, 2003）。AdE3-IAI处理。3B假设即使在治疗后约30天暂时缩小肿瘤，所有肿瘤在2-3周后复发的问题。这不仅在动物实验中得到证实，而且在使用其他溶瘤载体的临床试验中也得到证实。猜测是矢量从肿瘤向全身快速移位的一个原因，因为矢量在肿瘤中停滞率很少，在肿瘤中停滞时间短。AdE3-IAI之后。将3B感染到293和A549细胞上，这些细胞作为载体细胞被称为腺病毒产生细胞，并将这些载体细胞给予卵巢癌裸鼠皮下肿瘤模型PA-1和RMG-1细胞，更重要的是，IAI.3B启动子高，两种肿瘤完全消失，没有复发。另一方面，腺病毒受体少于这些细胞的HEY细胞肿瘤，两者联合使用时，肿瘤消失，不承认复发，而293或A549细胞感染AdE3-IAI.3B单细胞治疗后，肿瘤未消失。众所周知，腺病毒载体的第二次攻击完全被抗腺病毒抗体的产生所阻断。然而，腺病毒的第二次攻击通过使用AdE3-IAI获得了成功。3B感染293或A549载体细胞。第二次腺病毒感染的恢复被0。4微米的膜室和50%被12微米的膜室阻挡。这是由于通过载体细胞与靶细胞的直接接触和载体细胞片段与靶细胞的直接接触实现了感染。电镜下证实了这种溶瘤腺病毒感染载体细胞的感染方式。少

项目成果

期刊论文数量（38）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy.

人 IAI.3B 启动子元件的鉴定及其在构建用于卵巢癌治疗的复制选择性腺病毒中的应用。

DOI：
发表时间：
2003
期刊：
Cancer Res. 63
影响因子：
0
作者：
Hamada;K.;Kohno;S.;Iwamoto;M.;Yokota;H.;Okada;M.;Tagawa;M.;Hirose;S.;Yamasaki;K.;Shirakata;Y.;Hashimoto;K.;Ito;M.
通讯作者：
M.

癌遺伝子治療薬

癌症基因治疗药物